Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17291834 | 0.84 | KMT2A (0.41) | MAPTKMT2ADRD1ALDH1A1 | |
| SCHEMBL2712275 | 0.84 | — | — | |
| SCHEMBL10475292 | 0.80 | ADH1B (0.46) | KMT2ADRD1RAB9AEPHX2ALDH1A1 | |
| SCHEMBL26027071 | 0.80 | SAT1 (0.33) | — | |
| SCHEMBL5360130 | 0.79 | KCNH3 (0.37) | RAB9AEPHX2KCNH3NAMPTALDH1A1 | |
| SCHEMBL5545183 | 0.78 | ADH1B (0.50) | KMT2ADRD1EPHX2ALDH1A1 | |
| SCHEMBL25845711 | 0.76 | SAT1 (0.38) | NAMPT | |
| SCHEMBL28707592 | 0.76 | NPC1 (0.34) | RAB9AEPHX2KCNH3NAMPT | |
| SCHEMBL3259366 | 0.75 | GNAI3 (0.44) | KMT2AEPHX2 | |
| SCHEMBL10399362 | 0.75 | KMT2A (0.35) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3978076-A1 | CYCLIC AMIDE COMPOUNDS FOR RABIES TREATMENT AND METHOD THEREOF | Oita University Institute of Advanced Medicine, Inc. (JP) | 2022-04-06 | — | — | EP | disclosed |
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054623-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | MAPT 3787/4885KMT2A 4253/4885DRD1 4283/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | MAPT 3787/4885KMT2A 4253/4885DRD1 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.